Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidaza for prevention of AML and MDS relapse post-transplant
NCT00887068Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2009
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2009; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT00887068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887068.